/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Gilead Sciences Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$125.2 0.0088(0.88%) GILD at 04 Dec 2025 04:33 PM Drug Manufacturers - General
Lowest Today 123.91
Highest Today 125.55
Today’s Open 124.045
Prev. Close 123.91
52 Week High 128.70
52 Week Low 86.73
Day’s Range: Low 123.91 High 125.55
52-Week Range: Low 86.73 High 128.70
1 day return -
1 Week return -0.68
1 month return +1.62
3 month return +10.87
6 month return +14.65
1 year return +36.49
3 year return +42.08
5 year return +103.05
10 year return -

Institutional Holdings

Vanguard Group Inc 9.62

BlackRock Inc 9.26

FMR Inc 4.83

State Street Corp 4.77

Capital World Investors 3.73

Vanguard Total Stock Mkt Idx Inv 3.15

Wellington Management Company LLP 3.02

Capital Research Global Investors 2.51

Dodge & Cox 2.48

Vanguard 500 Index Investor 2.48

Geode Capital Management, LLC 2.35

Invesco QQQ Trust 2.07

T. Rowe Price Associates, Inc. 1.90

Dodge & Cox Stock I 1.85

Morgan Stanley - Brokerage Accounts 1.84

American Funds Income Fund of Amer A 1.60

NORGES BANK 1.56

JPMorgan Chase & Co 1.54

Bank of America Corp 1.53

UBS Asset Mgmt Americas Inc 1.34

Fidelity 500 Index 1.27

SPDR® S&P 500® ETF 1.21

iShares Core S&P 500 ETF 1.21

Northern Trust Corp 1.16

Bank of New York Mellon Corp 1.11

Amvescap Plc. 1.09

American Funds Washington Mutual A 1.08

Capital Group Wash Mutual Invtrs Comp 1.08

Vanguard Value Index Inv 0.89

Amundi 0.84

Dimensional Fund Advisors, Inc. 0.82

American Funds American Balanced A 0.80

Vanguard Equity-Income Inv 0.74

American Funds Capital Income Bldr A 0.71

The Health Care Select Sector SPDR® ETF 0.68

Vanguard Institutional Index I 0.61

Vanguard Wellington™ Inv 0.55

State St S&P 500® Indx SL Cl III 0.54

American Funds American Mutual A 0.52

Capital Group American Mutual Comp 0.52

Market Status

Strong Buy: 15

Buy: 4

Hold: 11

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 153748.39 M

PB Ratio 7.1613

PE Ratio 19.2407

Enterprise Value 171845.70 M

Total Assets 58995.00 M

Volume 5306324

Company Financials

Annual Revenue FY24:28754000000 28754.0M, FY23:27391000000 27391.0M, FY22:27281000000 27281.0M, FY21:27305000000 27305.0M, FY20:24689000000 24689.0M

Annual Profit FY24:78200000 78.2M, FY23:21587000000 21587.0M, FY22:21624000000 21624.0M, FY21:20704000000 20704.0M, FY20:20117000000 20117.0M

Annual Net worth FY24:480000000 480.0M, FY23:5876000000 5876.0M, FY22:4592000000 4592.0M, FY21:6225000000 6225.0M, FY20:89000000 89.0M

Quarterly Revenue Q3/2025:7769000000 7769.0M, Q2/2025:7081000000 7081.0M, Q1/2025:6667000000 6667.0M, Q4/2024:7569000000 7569.0M, Q3/2024:7545000000 7545.0M

Quarterly Profit Q3/2025:6200000000 6200.0M, Q2/2025:5580000000 5580.0M, Q1/2025:5127000000 5127.0M, Q4/2024:79000000 79.0M, Q3/2024:5971000000 5971.0M

Quarterly Net worth Q3/2025:3052000000 3052.0M, Q2/2025:1960000000 1960.0M, Q1/2025:1315000000 1315.0M, Q4/2024:1783000000 1783.0M, Q3/2024:1253000000 1253.0M

Fund house & investment objective

Company Information Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Organisation Drug Manufacturers - General

Employees 17600

Industry Drug Manufacturers - General

CEO Mr. Daniel P. O'Day

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow